Group 1 - The company Shengtun Mining has been fined 3 million yuan by the China Securities Regulatory Commission (CSRC) for financial misconduct related to revenue recognition from sales of cobalt intermediate products between December 2021 and the first half of 2023 [1][2] - The CSRC's investigation revealed that the company recognized revenue without the actual transfer of control over the goods, leading to significant discrepancies in financial reporting [1][3] - The financial misstatements included an overstatement of operating income by 359 million yuan and total profit by 194 million yuan in the 2021 annual report, an overstatement of operating income by 84.149 million yuan and understatement of total profit by 13.9 million yuan in the 2022 annual report, and an understatement of operating income by 78.188 million yuan and total profit by 22.957 million yuan in the 2023 semi-annual report [3] Group 2 - Investors who purchased shares between April 26, 2022, and April 21, 2024, and sold or still hold them after April 22, 2024, while incurring losses, are eligible to pursue claims against the company [2][4] - The statute of limitations for such claims is three years, and investors are advised to prepare relevant evidence, including stock trading records, to support their claims [4] - The legal team led by lawyer Liu Peng will assist investors in formulating appropriate litigation strategies based on the evidence provided [4]

Group 1 - Taiyuan Heavy Industry announced on October 31 that it and related parties received an administrative penalty notice from the Shanxi Securities Regulatory Bureau [1][4] - The company is accused of manipulating financial data related to the "300MW Wind Power Project" in collaboration with Heilongjiang Ruihao Technology Group [4] - Investors who purchased shares between April 11, 2015, and July 25, 2025, and incurred losses can register for compensation [4][5] Group 2 - The company has a history of financial misreporting, with 7.57 billion yuan of revenue overstated in 2014, representing 8.39% of the reported revenue, and 1.55 billion yuan of profit overstated, which is 763.89% of the reported profit [2][4] - From 2014 to 2018 and in 2020 to 2021, Taiyuan Heavy Industry reported various degrees of overstatements or understatements in revenue, costs, and profits [2][4] - In 2016, the company overstated revenue by 7.52 billion yuan, accounting for 17.58% of the reported revenue for that year [2][4]

Group 1 - The core issue involves Xiangxue Pharmaceutical facing administrative penalties totaling 20.65 million yuan due to related party fund occupation and five years of financial fraud [1][2][3] - The company was found to have falsely reported profits in its 2019 annual report, inflating profits by 53.83 million yuan, which accounted for 45.98% of the total disclosed profit for that year [3] - The company failed to disclose losses from the demolition of five villas in December 2019, leading to significant omissions in its financial statements from 2016 to 2020 [3] Group 2 - Two categories of investors are eligible for compensation: those who bought shares between May 20, 2020, and April 29, 2024, and sold or still hold them at a loss after April 30, 2024, and those who bought shares between March 25, 2017, and September 30, 2024, and sold or still hold them at a loss after October 1, 2024 [4] - The legal actions are being supported by the recent regulatory penalties, which will serve as strong evidence in the upcoming investor compensation lawsuits [4]

Group 1 - The company is currently collecting claims from investors affected by its previous financial misconduct, with a legal team actively assisting hundreds of investors in filing cases [1][2][3] - The compensation is available for investors who purchased shares between April 28, 2023, and April 25, 2024, and either sold or still hold shares at a loss after April 26, 2024 [1][2] - The legal team aims to ensure fair and just handling of the cases, which are currently under further review [3] Group 2 - The company has faced severe penalties for financial fraud, including false disclosures in its financial reports for the first three quarters of 2023 [4] - Specific fraudulent activities included the premature recognition of revenue from prepayments for pig vaccines and the creation of fictitious sales and expenses [4] - The company is also under scrutiny for potential legal accountability of its securities service providers if they failed to fulfill their oversight responsibilities [4]

Group 1 - The core issue involves investor lawsuits against Langyuan Co., Ltd. due to violations of information disclosure, with multiple cases currently under judicial review [1][4] - The lawsuits stem from financial fraud related to the performance commitments of a subsidiary, resulting in significant consequences for Langyuan and its executives [1][4] - Investors who suffered losses due to false statements made by the company are eligible for civil compensation under relevant laws, with specific time frames outlined for claims [1][4] Group 2 - On April 28, Langyuan announced it received an administrative penalty decision from the Shandong Securities Regulatory Bureau, following an investigation into its financial reporting [2][5] - The investigation revealed that in December 2018, Langyuan acquired 51% of Guangdong Youshi, which was then included in its consolidated financial statements [2][5] - In 2019, to meet performance commitments, the subsidiary engaged in fictitious transactions to inflate revenue, costs, and profits, leading to false financial statements for that year [2][5] - Despite a correction announcement in September 2020, the revised financial data still contained inaccuracies, prompting severe penalties from the regulatory authority [2][5]

Group 1 - The company received an administrative penalty from the China Securities Regulatory Commission (CSRC) on October 14, 2024, due to false records in the 2022 annual audit report issued by Da Xin Accounting Firm, resulting in a total penalty of 509.4 thousand yuan [1] - The audit firm was found negligent in its duties during the audit of the company's financial statements, leading to the confiscation of audit income amounting to 169.8 thousand yuan and a fine of 339.6 thousand yuan [1] - The penalties indicate that the audit firm will be added as a defendant in subsequent investor compensation procedures, highlighting the increased accountability for information disclosure under the new securities law [1] Group 2 - The CSRC imposed a total fine of up to 19 million yuan on the company and related responsible persons for fabricating delivery documents to prematurely recognize real estate business income, which inflated revenue, costs, and profits [2] - Investors who purchased shares between April 11, 2023, and April 29, 2024, and sold or still hold the stock after April 30, 2024, while suffering losses, are eligible to join the compensation efforts [2] - The inaccuracies in the company's annual and semi-annual reports are likely to mislead investors, potentially resulting in investment losses [2]

一、部分案件获法院受理 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 近日，上海沪紫律师事务所刘鹏律师团队代理的案件获法院受理并选定某投资者案件作为示范性案例。 （刘鹏律师专栏） 回溯此案，2025年11月28日，沈阳化工收到一纸来自中国证券监督管理委员会辽宁监管局的《行政处罚 决定书》，为其长达四年的系统性财务造假行为画上了句点。 现符合于2019年3月21日-2023年4月28日（含当日）期间买入，并在2023年4月29日之后卖出或仍持 有而亏损的即可参与维权。对此，辽宁证监局拟决定对沈阳化工给予警告，并处以700万元罚款，相关 责任人纷纷被罚。（沈阳化工维权入口） 这不仅是一场对公司治理和内部控制的拷问，更对资本市场诚信和投资者权益造成了严重损害。目前符 合要求皆可加入。 二、多年财报存在造假 据监管调查，公司的全资子公司沈阳石 ...

Group 1 - The core issue revolves around the financial misconduct of Puli Pharmaceutical, which inflated profits by over 669 million yuan over two years, leading to a court ruling in favor of investors seeking compensation for their losses [1][3] - The Haikou Intermediate People's Court has ruled that Puli Pharmaceutical must compensate investors who suffered losses due to false financial reports, with the possibility of an appeal leading to a second trial [1][3] - The company was found to have fabricated sales of finished and raw pharmaceutical products, resulting in a total of 1.031 billion yuan in inflated revenue and 695 million yuan in inflated profits for the years 2021 and 2022, which constituted 31.08% and 76.72% of the reported annual figures, respectively [1][3] Group 2 - Investors who purchased shares between April 26, 2022, and April 16, 2024, and sold or still hold shares after April 17, 2024, are eligible to register for compensation [1][3] - The China Securities Regulatory Commission (CSRC) has stated that it will assist eligible investors in their claims against the company for losses incurred due to financial fraud [2][4] - The focus for investors now shifts to how the court will determine the compensation ratio and whether Puli Pharmaceutical has the financial capacity to pay [2][4]

一、监管下发正式处罚 绝味食品作为"鸭脖大王"备受消费者和投资者青睐，如今却因信息披露违法违规陷入困境。刚在9月， 公司就收到湖南证监局下发的《行政处罚决定书》。如今还需面临投资者索赔事宜。 上海沪紫律师事务所刘鹏律师提示目前维权征集正式开启，信符合于2018年4月16日-2024年8月15日 （含当日）期间买入，并在2024年8月16日之后卖出或仍持有而亏损的即可参与。（绝味食品维权入 口） 此次投资者索赔事宜也引起了市场广泛关注，众多受损投资者纷纷响应维权征集，期望通过合法途径挽 回自身损失，同时也希望以此促使上市公司更加规范运作，保障资本市场的健康稳定发展。 二、多年财报虚假记载 登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ （本文由上海沪紫律师事务所刘鹏律师供稿，不代表新浪财经的观点。刘鹏律师，专注证券维权19年， 自2006年执业以来，成功为中青宝、国华网安、劲嘉股份（维权）等 30 ...

受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 一、监管下发正式处罚 一笔3000万元的技术转让交易，在证监会的调查下显露出"循环增资"的真相，最终化为4740万元的高额 罚单，压在了诺泰生物的肩头。 登录新浪财经APP 搜索【信披】查看更多考评等级 登录新浪财经APP 搜索【信披】查看更多考评等级 12月17日晚，ST诺泰（维权）发布关于收到《行政处罚决定书》的公告，公司及相关责任人被处罚。 上海沪紫律师事务所刘鹏律师代理的案件也已陆续递交立案，等待法院审理中。上市公司信息披露违法 违规行为不仅严重扰乱证券市场秩序，更是对股民合法权益的严重侵害。根据相关法律法规，受损投资 者可提起诉讼，要求上市公司赔付损失。（刘鹏律师专栏） 索赔条件为于2022年4月28日-2024年10月23日（含当日）之前买入，并在2024年10月24日之后卖出 或仍持有而亏损的还可加入。（诺泰生物维权入口） 二、财报造假被重罚 据处罚决定，该公司2021年年报存在虚假 ...